Annals ofHIV - Aids

Volume: 5 - Number: 38 - February 15, 2006

Outstanding

Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment.

First-line efavirenz versus lopinavir-ritonavir-based highly active antiretroviral therapy for naive patients.

Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapy.

Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir.

BASIC SCIENCE

New CCR5 variants associated with reduced HIV coreceptor function in southeast Asia.

Incidence immunoassay for distinguishing recent from established HIV-1 infection in therapy-naive populations.

Cellular HIV-1 DNA load predicts HIV-RNA rebound and the outcome of highly active antiretroviral therapy.

CLINICAL SCIENCE

A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV.

Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir.

Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome.

Editorial reviews

Special considerations in the initiation and management of antiretroviral therapy in individuals coinfected with HIV and hepatitis C .

Barriers to participating in an HIV vaccine trial: a systematic review.

Epidemiology

Global overview of injecting drug use and HIV infection among injecting drug users.

Factors associated with a decrease in the prevalence of drug resistance in newly HIV-1 infected individuals in Montreal.

The effect of hepatitis C on progression to AIDS before and after highly active antiretroviral therapy

Infection with concurrent multiple hepatitis C virus genotypes is associated with faster HIV disease progression.

NOTES & QUOTES

NOTES & QUOTES

Research letters

Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment.

Predicted genotypic resistance to the novel entry inhibitor, BMS-378806, among HIV-1 isolates of subtypes A to G.

Viral load and CD4 cell response to protease inhibitor-containing regimens in subtype B versus non-B treatment-naive HIV-1 patients.

First-line efavirenz versus lopinavir-ritonavir-based highly active antiretroviral therapy for naive patients.

Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapy.

Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe.

Changes in HIV prevalence among young Thai men as defined by hepatitis C co-infection as a marker for mode of transmission.